Combination, Miltefosine Monotherapy & Antimonial Therapy for Cutaneous Leishmaniasis in New World
Status:
Recruiting
Trial end date:
2023-03-30
Target enrollment:
Participant gender:
Summary
This study evaluates if the combination of thermotherapy (one application, 50⁰C for 30") and
3 weeks of miltefosine is safe and have a comparable cure rate with the current recommended
first line treatments comprising meglumine antimoniate for 3 weeks or miltefosine monotherapy
for 4 weeks, for the treatment of uncomplicated cutaneous leishmaniasis cases in the New
World.